Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | ANPEP | P15144 | 1/20 | 0.37 |
| ▸ | PDE4A | P27815 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3371743 | 0.98 | KDM4E (0.56) | KDM4ETDP1LMNAL3MBTL1ANPEP | |
| SCHEMBL3685829 | 0.98 | KDM4E (0.56) | KDM4ETDP1LMNAL3MBTL1ANPEP | |
| SCHEMBL3371251 | 0.98 | KDM4E (0.56) | KDM4ETDP1LMNAL3MBTL1ANPEP | |
| SCHEMBL3800695 | 0.98 | KDM4E (0.56) | KDM4ETDP1LMNAL3MBTL1ANPEP | |
| SCHEMBL17833039 | 0.94 | KDM4E (0.50) | KDM4ETDP1LMNAL3MBTL1ANPEP | |
| SCHEMBL3680834 | 0.86 | KDM4E (0.52) | KDM4ETDP1LMNAL3MBTL1ANPEP | |
| SCHEMBL22321686 | 0.86 | KDM4E (0.52) | KDM4ETDP1LMNAL3MBTL1ANPEP | |
| SCHEMBL3373994 | 0.86 | KDM4E (0.52) | KDM4ETDP1LMNAL3MBTL1ANPEP | |
| SCHEMBL17833157 | 0.85 | ANPEP (0.41) | KDM4ETDP1LMNAL3MBTL1ANPEP | |
| Hydrochloric Acid SCHEMBL7165571 | 0.84 | KDM4E (0.50) | KDM4ETDP1LMNAL3MBTL1ANPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4225479-B1 | FILTRATION MEMBRANE SYSTEMS, AND METHODS FOR PRODUCING PURIFIED WATER | ENTEGRIS INC (US) | 2026-05-06 | — | — | EP | disclosed |
| US-20250144574-A1 | FILTRATION MEMBRANES, SYSTEMS, AND METHODS FOR PRODUCING PURIFIED WATER | ENTEGRIS, INC. | 2025-05-08 | — | — | US | disclosed |
| US-20240367116-A1 | LIGAND-MODIFIED FILTER AND METHODS FOR REDUCING METALS FROM LIQUID COMPOSITIONS | ENTEGRIS, INC. | 2024-11-07 | — | — | US | disclosed |
| EP-4225479-A1 | FILTRATION MEMBRANES, SYSTEMS, AND METHODS FOR PRODUCING PURIFIED WATER | Entegris, Inc. (US) | 2023-08-16 | — | — | EP | disclosed |
| CN-111545075-B | Ligand-modified filter materials, composite membranes, and methods for reducing metals from liquid compositions | 恩特格里斯公司 | 2023-08-01 | — | — | CN | disclosed |
| US-20220410084-A1 | LIGAND-MODIFIED FILTER AND METHODS FOR REDUCING METALS FROM LIQUID COMPOSITIONS | MORGAN STANLEY SENIOR FUNDING, INC., AS COLLATERAL AGENT | 2022-12-29 | — | — | US | disclosed |
| US-11465104-B2 | Ligand-modified filter and methods for reducing metals from liquid compositions | ENTEGRIS, INC. (US) | 2022-10-11 | — | — | US | disclosed |
| EP-3468996-B1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | ABBVIE INC (US) | 2022-05-04 | — | — | EP | disclosed |
| US-20220111337-A1 | Filtration Membranes, Systems, and Methods for Producing Purified Water | ENTEGRIS, INC. | 2022-04-14 | — | — | US | disclosed |
| WO-2022076249-A1 | FILTRATION MEMBRANES, SYSTEMS, AND METHODS FOR PRODUCING PURIFIED WATER | ENTEGRIS, INC. (US) | 2022-04-14 | — | — | WO | disclosed |
| EP-3921067-A1 | LIGAND-MODIFIED FILTER AND METHODS FOR REDUCING METALS FROM LIQUID COMPOSITIONS | Entegris, Inc. (US) | 2021-12-15 | — | — | EP | disclosed |
| CN-111545075-A | Ligand-modified filter materials, composite membranes and methods for reducing metals from liquid compositions | 恩特格里斯公司 | 2020-08-18 | — | — | CN | disclosed |
| WO-2020163181-A1 | LIGAND-MODIFIED FILTER AND METHODS FOR REDUCING METALS FROM LIQUID COMPOSITIONS | ENTEGRIS, INC. (US) | 2020-08-13 | — | — | WO | disclosed |
| US-20200254398-A1 | LIGAND-MODIFIED FILTER AND METHODS FOR REDUCING METALS FROM LIQUID COMPOSITIONS | MORGAN STANLEY SENIOR FUNDING, INC., AS COLLATERAL AGENT | 2020-08-13 | — | — | US | disclosed |
| WO-2017214282-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | ABBVIE INC. (US) | 2017-12-14 | — | — | WO | disclosed |
| WO-2017214335-A1 | ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | ABBVIE INC. (US) | 2017-12-14 | — | — | WO | disclosed |
| WO-2017214462-A2 | ANTI-CD98 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | ABBVIE INC. (US) | 2017-12-14 | — | — | WO | disclosed |
| US-20170355769-A1 | ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | ABBVIE INC. | 2017-12-14 | — | — | US | disclosed |
| US-20160339117-A1 | BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the Same | ABBVIE INC. (US) | 2016-11-24 | — | — | US | disclosed |
| WO-2016094509-A1 | BCL XL INHIBITORY COMPOUNDS HAVING LOW CELL PERMEABILITY AND ANTIBODY DRUG CONJUGATES INCLUDING THE SAME | ABBVIE INC. (US) | 2016-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355769-A1 | ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | HRH3, H1-3, CD274 | KDM4E 424/4885TDP1 4467/4885LMNA 4613/4885 |
| US-20160339117-A1 | BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the Same | BCL2, BAX, BCL9 | KDM4E 1299/4885TDP1 3899/4885LMNA 1814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.